Efficacy of artemether-lumefantrine treatment in uncomplicated malaria (Plasmodium falciparum) patients and in-vitro experiment on susceptibility of malaria (P. falciparum) strains to new chemical substances

ISRCTN ISRCTN08391109
DOI https://doi.org/10.1186/ISRCTN08391109
Secondary identifying numbers N/A
Submission date
18/06/2009
Registration date
30/06/2009
Last edited
11/05/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Infections and Infestations
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Peter Odermatt
Scientific

Swiss Tropical Institute
Dept. Public Health and Epidemiology
Socinstrasse 57
Postfach
4002 Basel
Basel
4002
Switzerland

Study information

Study designUnblinded, single-arm efficacy trial
Primary study designInterventional
Secondary study designNon randomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleSusceptibility of Plasmodium falciparum from Southern Laos to artemether-lumefantrine and new chemical entities: in-vivo and in-vitro studies in the province of Attapeu, Laos
Study acronymSPfL
Study objectivesMalaria parasite (P. falciparum) of southern Laos is susceptible to artemether-lumefantrine (in vivo) and also to new chemical entities (in-vitro).

As of 11/05/2010 this record was updated to include an extended anticipated end date; the intial anticipated end date at the time of registration was 31/12/2009.
Ethics approval(s)Ethical Committee of the Kanton of Basel (Ethikkommission beider Basel) approved on the 21st April 2009 (ref: 131/09)
Health condition(s) or problem(s) studiedUncomplicated P. falciparum malaria infection
InterventionAll subjects will receive treatment with artemether-lumefantrine (standard protocol). Patients will be followed up daily until day 7 and then weekly until 42 days.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase IV
Drug / device / biological / vaccine name(s)Artemether-lumefantrine
Primary outcome measureParasite clearance time, assessed daily after until day 7
Secondary outcome measures1. Early treatment failure, measured by malaria symptoms present on day 3 after treatment start
2. Late treatment failure, measured by malaria symptoms on any follow-up after day 7
3. Late parasitological failure, measured by parasite present on any follow-up after day 7
Overall study start date06/07/2009
Completion date01/03/2011

Eligibility

Participant type(s)Patient
Age groupOther
SexBoth
Target number of participants110
Key inclusion criteria1. Male or female aged greater than 1 year
2. Fever (axillary, 37.5ºC) on admission, or reported history of fever within the last 72 hours (3 days)
3. Willingness to participate in particular to stay at the hospital for the first 7 days
4. Full written informed consent (signed) provided by themselves or by attending relatives
5. Signed pre-consent if patient was referred from a district hospital or dispensary
6. Willing to stay under close medical supervision at the hospital for the study duration of at 7 days, and willingness to participate weekly until the 6th week (42 days follow-up)
Key exclusion criteria1. Pregnancy: all females (aged 12 - 50 years) are required to have a "negative" pregnancy test (urine) or are currently using an acceptable method of contraception
2. Lactating mother
3. Intake of anti-malarial drugs for the last 3 days (reported on admission, urine samples for confirmation)
4. Mixed malaria infection on admission, i.e. P. falciparum and any other Plasmodium species
5. A previous history of intolerance or hypersensitivity to the study drugs artemether-lumefantrine or to drugs with similar chemical structures, such as artemether, artemisinin or dihydroartemisinin and lumefantrine-like compounds
6. History of significant cardiovascular, liver or renal functional abnormality or any other clinically significant illness
7. Symptoms of severe vomiting
8. Signs or symptoms of severe malaria (World Health Organization [WHO] 2003)
9. Unable to follow the protocol
10. Age of 12 months and below
Date of first enrolment06/07/2009
Date of final enrolment01/03/2011

Locations

Countries of recruitment

  • Lao People's Democratic Republic
  • Switzerland

Study participating centre

Swiss Tropical Institute
Basel
4002
Switzerland

Sponsor information

Medicines for Malaria Venture (MMV) (Switzerland)
Research organisation

PO Box 1826
20, rte de Pré-Bois
Geneva 15
1215
Switzerland

Phone +41 (0)22 799 4060
Email info@mmv.org
Website http://www.mmv.org
ROR logo "ROR" https://ror.org/00p9jf779

Funders

Funder type

Research organisation

Medicines for Malaria Venture (MMV) (Switzerland)
Private sector organisation / Other non-profit organizations
Alternative name(s)
MMV
Location
Switzerland

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan